Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Brief summary (registry, in English)

The purpose of this study is to continue to provide elotuzumab and/or other study drugs to participants who have participated on a prior protocol investigating elotuzumab who are not able to receive commercial drug supply.

What you commit to

• Study type: Interventional · Phase 2
• Participants enrolled: 67
• From 15 Jul 2016 to the primary completion date, 23 Feb 2026
• 41 sites in 13 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (41)

Sites in registry order. Pick your city on the disease page to sort them by distance.